White blood cell (WBC) ? 50 × 10^3/?L

White blood cells (WBC) > 3 x 10^9/L, within 28 days prior to administration of study treatment

White blood cell (WBC) >= 2000/uL

White blood count >= 3,000/uL, obtained within 4 weeks prior to randomization

White blood cell count (WBC) >= 2,000/mcL; must be obtained within 28 days prior to registration

White Blood Cell Count (WBC) Criteria\r\n* Age 1-9.99 years: WBC >= 50 000/uL \r\n* Age 10-30.99 years: Any WBC \r\n* Age 1-30.99 years: Any WBC with:\r\n** Testicular leukemia\r\n** CNS leukemia (CNS3)\r\n** Steroid pretreatment

White blood cells >= 2000/uL, within 4 weeks of randomization

White blood cell count >= 4000 cells/mm^3

For patients with AML or MDS, patient must have white blood cell count (WBC) ? 50,000/mL. Hydroxyurea is allowed to achieve this change but must be discontinued a minimum of five (5) days prior to baseline evaluation

White blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatment

White blood cells (WBC) >= 3,000 cells/uL (3.0 x 10^9 L) or

White blood cell (WBC) >= 3,000/ul

White blood cell count >= 2.5 x 10^3/mm^3

ELIGIBILITY CRITERIA - PHASE I (ARMS A, B, C): Circulating white blood cell (WBC) count must not be above 20 x10^9/L within 7 days prior to first dose of study agent\r\n* Patients with WBC count above 20 x 10^9/L may be eligible if they start steroids or hydroxyurea per institutional guidelines, but they must discontinue before day 1 of study drug

White blood cell (WBC) count ? 3 × 10e3/µL

Measured within 28 days prior to registration: white blood cells > 3,000/mcL

White blood cell (WBC) >= 2.0 x 10^9/L

White blood cells (WBC) > 15,000 cells/mcL (15 cells x 10^9/L) at screening. In subjects with WBC > 15,000 cells/mcL at screening with lymphocyte predominance, subject may be deemed eligible for the trial by the Amgen physician, after discussion with the investigator.

White blood cell (WBC) >= 3,000/uL

COHORT 1: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterion

COHORT 2: White blood cell (WBC) count =< 30,000 /mcL within 14 days of treatment initiation\r\n* NOTE: Hydroxyurea/leukapheresis use is allowed to meet this criterion

White blood cells (WBC) >= 3.0 x 10^9/L

White blood cell (WBC) >= 2,000/mm^3, performed within 14 days of treatment initiation

White blood cells (WBC) > 3 x 10^9/L

WBC =< 3 x 10^9/L

White blood cell (WBC) greater than or equal to 3,000/ul

White blood cell counts > 3000 cells/mcL

White blood cell (WBC) >= 3,000/mcL

White Blood Cell Count (WBC) > 3,000/µL

WBC ? 3.0 x 10e9/L

White blood cell (WBC) >= 3000/mcl

Obtained within 14 days prior to course 1 day 1 (C1D1): White blood cells (WBC) >= 2000/uL

Total white blood cells (WBC) < 2x10^9/L (2000/mm^3)

White blood cells (WBC) < 4,000

White blood cell count (WBC) < 2,000/µL

White Blood Cell (WBC) ?2000/?L (?2 x 10^9/L)

White blood cells (WBC) >= 3 x 10^9/L, completed within 14 days prior to the date of registration

White blood cells (WBC) >= 2000/uL

White blood cells >= 3,000/microliter

White blood cells (WBC) >= 3000/mm^3

White blood cell (WBC) ? 3.00 K/uL

White blood cells (WBC) >= 3,000/mm^3

White blood cell (WBC) > 2,000/mcL

White blood cell count (WBC) > 2500/uL

White blood cells (WBC) > 15,000 cells/mcL at screening

White blood cell (WBC) count >= 3,000/mcL

White blood cell count (WBC) > 2500 cells/mm^3

White blood cells (WBC) >= 2,500/mm^3

White blood cell (WBC) >= 2000/uL

Patients who have a white blood cell count less than 2,500 per cubic mm

White blood cells (WBC) >= 3,000/uL

Normal white blood cell count (WBC) (> 3000/mm^3)

White blood cell (WBC) > 3500/ul within four weeks of enrollment

White blood cells (WBC) >= 3000/mm^3

White blood cell count (WBC) >= 3.0 K/mm^3

PART I: White blood cell (WBC) >= 2,500 cells/mm^3

PART II: WBC >= 2,500 cells/mm^3

White blood cells (WBC) (> 3000/mm^3)

white blood cell (WBC)count >= 3,000/mm3.

White blood cells (WBC) >= 2.5

Normal white blood cell (WBC) (> 3000/mm^3)

White blood cell (WBC) count >= 3,000/uL

White blood cell (WBC) counts > 2500/uL.

Within 14 days of randomization: White blood cell (WBC) count >= 3 x 10^9/L

Within 14 days of the first dose of study drug: White blood cells (WBCs) >= 2000/uL

WBC < 2,000 uL

White blood cell (WBC) >= 3000/mm^3

White blood cell (WBC) count >= 3 × 10^9/L.

White blood cells (WBC) > 2,500/mcL

White blood cell (WBC) >= 3000/mm^3

Subject has a white blood cell count > 25 x 10^9/L. (Note: Hydroxyurea is permitted to meet this criterion.)

Subject has a white blood cell count > 25 × 109/L; note: hydroxyurea is permitted to meet this criteria

White blood cell (WBC) < 3,500/mm^3

White blood cell count (WBC) >= 2000/uL.

White blood cell (WBC) count >= 3 x 10^9/L

White blood cell (WBC) count >= 3 x 10^9/L (in absence of blood transfusion).

White blood cell (WBC) ? 1,500/mcL

Normal white blood cells (WBC) (> 3000/mm^3)

White blood cell count ? 10,000

Patients receiving other active treatment for their myeloid malignancy including investigational agents with the exception of hydrea for white blood cell (WBC) control

Obtained within 14 days prior to randomization/registration: white blood cell (WBC ) >= 2000/uL

White blood cell (WBC) > 2,000/dl (or absolute neutrophil count [ANC] > 1,000)

Within 28 days prior to administration of study treatment: White blood count (WBC) > 3 x 10^9/L

Patients with white blood cell (WBC) > 30,000 are not eligible to start therapy; however, it is permissible to use glucocorticoids and/or hydroxyurea to diminish peripheral WBC to less than 30,000 provided these agents are stopped at least 24 hours prior to the first dose of MLN0128 (TAK-228)

White blood cell count >= 2.0 x 10^9/L

White blood cell (WBC) count of > 3000/ul

White blood cell (WBC) counts > 2500/uL.

White blood cell (WBC) count < 50,000/uL before administration of pevonedistat on cycle 1 day 1; Note: hydroxyurea may be used to control the level of circulating leukemic blast cell counts to not lower than 10,000/uL during the study

White blood cell (WBC) >= 2,500 cells/uL

Obtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uL

White blood cell count > 3 K/uL

White blood cell count > 3 K/uL.

White blood cell count (WBC) >= 3,000/mm^3

White blood cells (WBC) >= 3000/mm^3

White blood cell count >= 2000/uL

Leukocytes (white blood cells [WBCs]) >= 3,000/uL.

White blood cell (WBC) >= 2000/uL within 14 days of registration

Within 7 days prior to administration of study treatment: White blood cells (WBC) > 3 x 10^9/L.

White blood cell count (WBC) >= 2.5 k/mm^3

Obtained within 21 days prior to randomization/registration: White blood cell (WBC) >= 2000/uL.

Obtained within 14 days of the first study treatment: White blood cell (WBC) count > 2500/uL

White blood cell (WBC) >= 3 x 10^9/L.

Subject has a white blood cell count > 25 x 10{

White blood cell count > 2500/uL

White blood cell (WBC) < 2.0 x 10^9/L (or absolute neutrophil count < 1000)

White blood cell (WBC) counts > 2500/uL

Total white blood cell count (WBC) >= 2,000 cells/mm^3 without growth factors within 1 week of the initiation of treatment

White blood cell (WBC) >= 3 x 10^9 cells/mL

Total white blood cell count (WBC) >= 3000/mm^3

White blood cells (WBC) >= 3000/mm^3

Obtained within 14 days prior to the first study treatment (cycle 1, day 1): white blood cell (WBC) counts > 2500/uL

STUDY TREATMENT: White blood cells (WBC) >= 2000/ul

White blood cell (WBC) count of >= 3000/ul

White blood cells (WBC) > 3 x 10^9/L

Leukocytes (white blood cell [WBC]) >= 3,000/uL

Patients with AML whose white blood cell count exceeds 25,000/mcL

White blood cell (WBC) >= 3.0 x 10^9/L

White blood cell count (WBC) >= 2000/uL

White blood cells (WBC) >= 3,000/uL

White blood cell (WBC) >= 2000/uL

white blood cell count (WBC) ? upper limit of normal (ULN);

White blood cell (WBC) >= 2000/uL, within 30 days before study registration

White blood cells (WBC) >= 2000/uL within 14 days prior to first dose

White blood count (WBC) >= 2000/mcL, performed within 14 days of protocol registration

White blood cells (WBC) >= 3 x 10^9 cells/mL

White Blood Cell (WBC) ? 2500 cells/mm3

White blood cells (WBC) >= 2000/uL

White blood cells >= 3000/uL obtained < 4 weeks prior to starting treatment

WBC >2500/mm3

White blood cell (WBC) >= 3000/mm^3 obtained =< 7 days prior to registration

White blood cell (WBC) > 3000/mm^3, within 28 days prior to registration

Obtained within 14 days of randomization: White blood cells (WBCs) >= 2000/uL

White blood cell (WBC) < 2,000/mm^3

Peripheral white blood cell count < 50,000/mcl (patients may receive hydroxyurea as necessary for cytoreduction)

White blood cell (WBC) >= 3,000/mcL

White blood cell (WBC) within 10% of upper and lower limit of normal range of test

Sufficient bone marrow capacity as defined by WBC (white blood cell ) ?2.500/?l, PLT (platelet) count ?100.000/?l, Hb?9.9 g/dl and ANC?1500 mm3 for the first cycle and WBC?2.000/ ?l,PLT count ?75.000/?l, Hb?8.9 g/dl and ANC?1000 mm3 for the subsequent cycles

White blood cell (WBC) >= 2000/mm^3

White blood cells (WBC) >= 3000/mm^3 within 30 days of enrollment to study

Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts > 2500/uL

White blood cell (WBC) counts > 2500/uL

Performed within 14 days (+ 3 working days) prior to registration: White blood cell (WBC) > 3,000/ul.

White blood cells (WBC)\t>= 2,000/uL

White blood cell count (WBC) >= 3,000/uL

Total white blood cell (WBC) count >= 3000/uL, within 14 days of study registration (within 30 days for pulmonary and cardiac assessments)

White blood cell (WBC) >= 2500 cells/uL (obtained within 28 days prior to first study treatment)

Within 14 days of registration: White blood cell (WBC) > 3 x 10^9/L

White blood cell (WBC) counts > 2500/uL within 14 days prior to the first study treatment (cycle 1, day 1)

White blood cell (WBC) > 50,000/mcL

White blood cell (WBC) count >= 3,000/mm^3 obtained =< 14 days prior to registration

White blood count >= 3000/mm^3

White blood cells (WBC) >= 3,000/mcL

White blood cells (WBC) >= 2000/uL

Circulating white blood cells < 25.1000000000 /L (with or without use of hydroxycarbamide).

White blood cells (WBC) =< 10 x 10^9/L

White blood cell count (WBC) >= 2000/uL should be obtained within 21 days prior to enrollment

White blood cell count (WBC) > 3 x 10^9/L

White blood cells (WBC) > 3,000 cells/mm^3

Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment

Disease status allows delay of additional anti-leukemia therapy for the duration of the study (hydroxyurea is allowed for control of white blood cell count [WBC] throughout study)

WBC ?2000/uL

White blood cells (WBC) >= 2000 /uL

White blood cells (WBC) >= 2,000/mcL

White blood cells (WBC) >= 3000/mm^3

White blood cells (WBC) >= 3.0 x 10^9/L

White blood cells >= 3000/mm^3

White blood cell (WBC) >= 3000/uL

White blood cell (WBC) >= 3000/mm^3

White blood cell count (WBC) ? 3.0 x 109/L

White blood cells (WBC) >= 3 x 10^9 cells/ml

White blood cells (WBC) =< 10,000/uL

The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to study day 0 enrollment

White blood cells (WBC) >= 3,000/mcL

White blood cells (WBC) > 3000/mm^3

White blood cell count (WBC) >= 2500/mm^3

White blood count < 30,000/uL

White blood cell (WBC) of 2,000 per microliter (mcL)

White blood cell count (WBC)\t>= 2,000 /mcL

White blood cell count >= 3,500 cells/mm^3

White blood cell >= 2,500 cells/ul without growth factor support

White blood cell (WBC) >= 3000/mm^3

White blood count (WBC) >= 2000/uL obtained within 14 days prior to randomization/registration

White blood cells (WBC) < 200/mcl

White blood cell count > 2,500 cells/mcL

White blood cell count (WBC) >= 2.0 x 10^9/L

White blood cell (WBC) count at randomization less than or equal to (</=) 50000 cells per cubic millimeter (/mm^3)

White blood cell counts (WBC) > 2500/uL

White blood cell >= 2000/uL

Patient must have no persistent toxicities from prior therapy >= grade 2 with the exception of\r\nhematologic indices (i.e., hemoglobin, white blood cell count [WBC], ANC, absolute lymphocyte count [ALC])

Within 14 days prior to study entry: White blood cell (WBC) >= 2000/uL

Within 6 weeks of day 1: White blood cells (WBC) >= 2000/mm^3

White blood cell (WBC) >= 3,000/mm3

White blood cells (WBC) > 3x10^9/L (measured within 28 days prior to administration of study treatment)

White blood cell count (WBC) > 3000 within 30 days of consent

White blood cell (WBC) > 3000 within 45 days of consent

White blood cell (WBC) > 3.0 x 10^9/L within 14 days of study entry

White blood cell (WBC) < 2,500/mm^3

Documented white blood cell count of >= 3,000

White blood cell count (WBC) >= 2000/uL

White blood cells (WBC) >= 3,000/uL

White blood cell (WBC) count > 2500/uL

Presence of active central nervous system (CNS) leukemia - cerebrospinal fluid (CSF) with < 5 white blood count (WBC)/uL will not exclude the patient

White blood cells (WBC) > 3.0

Must be met within 28 days of course 1 day 1 (C1D1): White blood cell (WBC) >= 2,000/ul

White blood cell (WBC) >= 3,000/uL

White blood cell count (WBC) >= 3,000/mm^3

INCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: White blood cell count (WBC) >= 2,000/uL

White blood cells (WBC) < 3.5 K/mcL

White blood cells (WBC) >= 2500/uL

White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L

White blood cells (WBC) > 3000/mm^3

White blood cell (WBC) > 2,000/dl or

White blood cell (WBC) >= 3,000/uL obtained no more than 28 days prior to the start of neoadjuvant endocrine therapy

White blood cells (WBC) >= 3.0 x 10^9/L

Within 30 days of first vaccination: White blood cells (WBC) >= 3000/mm^3

White blood cells (WBC) >= 3000/mm^3

White blood cell (WBC) > 2000/mm^3

White blood cells (WBC) >= 3000/mm^3

a. WBC > 3,000/µL

White blood cell count (WBC) > 4000/mm^3

White blood cells (WBC) is >= 1500/ul

White blood cells (WBC) >= 2000/uL

White blood cells (WBC) >= 2,000/uL

White blood cells (WBC) >= 3000/mm^3

White blood cell (WBC) < 4,000

White blood cells (WBC) >= 3.0

White blood cell (WBC) >= 2,500 cells/uL

White blood cells (WBC) >= 3,000/mm^3

White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L

White blood cell count >= 1000/ul (phase I only)

White blood cell (WBC) with differential greater than 3,000/ml

White blood cells (WBC) >= 3.0

White blood cell >= 3500/ul

White blood cells (WBC) >= 3,000/ul

White blood cells (WBC) >= 3,000/mcL

White blood cell (WBC) >= 2000/uL

White blood count (WBC) > 2,500/uL

White blood cells (WBC) >= 3000/mm^3

White blood cells (WBC) >= 4,000/mm^3

White blood cell (WBC) >= 3.0 x 10^9/L (performed within 14 days prior to registration)

White blood cell count >= 1000/ul

White blood cells (WBC) >= 3,000/ul

White blood cell (WBC) >= 2000/uL

White blood cells (WBC) >= 4000/mm^3

White blood cells (WBC) >= 4000/mm^3

White blood cell count (WBC) > 3,000/mm^3

White blood cell (WBC) >= 2,000/ul

White blood cell (WBC) count >= 3,500/mm^3 within 7 days prior to starting treatment, OR

White blood cell (WBC) > 2.5 x 10^9/L with an absolute neutrophil count (ANC) > 1.5 x 10^9/L and off G-CSF or sargramostim (GM-CSF_ for 10 days or pegfilgrastim (Neulasta) for 21 days

White blood cell count >= 2.5 x 10^3/mm^3

White blood cell count >= 2.5 x 10^3/mm^3

White blood cell (WBC) count 3,000/mL

Hemoglobin level greater than (>) 10 gram per deciliter (g/dL) (following blood transfusion is acceptable) and normal white blood cell (WBC) and neutrophil counts (elevated WBC/absolute neutrophil count [ANC] attributed to steroid treatment is acceptable)

White blood count ? 3500 cells/mm3

White blood cell count ? 2000/?L

WBC>3000/mm3

White blood cells (WBC) >= 3 x 10^3/ul

White blood cell count (WBC) >= 3.5K/mm^3

White blood cells (WBC) >= 2,500/mm^3

White blood cells (WBC) >= 3000/ul performed within 60 days of enrollment

White blood cell (WBC) ? 3000/mm^3

Patients with uncontrolled white blood cell count (defined as > 50 K/cu mm not controlled with hydrea).

The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment

White blood cell count (WBC) t ? 2.5 x 109/L (2500/µL)

Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cell (WBC) counts >= 2500/uL.

Within 14 days prior to first dose of study drug treatment: White blood cell (WBC) >= 2.5 and =< 15.0 x 109/L

White blood cell (WBC) >= 3000/mm3

Peripheral blood leukocyte count (white blood cells [WBC]) < 3000/mm^3.

White blood cell (WBC) ? 3500 cells/mm^3 ? 2 weeks

DONORS: White blood cells (WBC) within 10% of upper and lower limit of normal range of test (gender based for hemoglobin)

Receipt of any anti-cancer therapy within 14 days prior to study entry, with the exception of hydroxyurea; if clinically indicated in order to keep white blood cells (WBC) < 30,000/uL, hydroxyurea may be continued through the first cycle

WBC (white blood cell count) is 2000/ul

White blood cell (WBC) >= 3.0 x 10^3/ul

White blood cell (WBC) less than or equal to 2000/uL

White blood cell (WBC) counts > 2500/uL, obtained within 14 days prior to the first study treatment (cycle 1, day 1)

Total absolute phagocyte count (APC = [%neutrophils + %monocytes) x white blood cells [WBC]) is at least 1000/uL

White blood count >= 3,000/uL

Performed within 14 days prior to study: White blood count (WBC) > 3,000/ul

White blood cells (WBC) >= 2,000/mcL

White blood cells (WBC) >= 2000/uL

White blood cells 2000/ul or more

White blood cell count >= 3,000 /ul

Obtained within 30 days prior to registration: White blood cell (WBC) >= 2 k/mm^3

White blood cell count (WBC) >= 3 x 10^9/L

White blood count > 3,000/mcL

Step 2: White blood count > 3,000/mcL

White Blood Cell count (WBC) < 4,000/µL

Total white blood cell count ?200,000/mm3

White blood cell (WBC) >= 2.0 x 10^3/ul

WBC >= 2.0 x 10^3/ul

White blood cells (WBC) > 3000/mcL

White blood cell (WBC) >= 3,000/uL

White blood cells (WBC) >= 3500/uL

White blood cell (WBC) >= 4000/ml

White blood cell (WBC) counts > 2500/uL

White blood cell (WBC) count >= 50,000 on hydroxyurea

DONOR: White blood cells (WBC), platelet count near normal limits (± 10%)

White blood cells (WBC) >= 3000/uL

White blood cells (WBC) >= 3000/mm^3

White blood count >= 3,000/mm^3

White blood cell (WBC) >= 2,500 cells/uL

White blood cells (WBC) > 3 x 10^9/L, measured within 28 days prior to administration of study treatment

White blood cells (WBC) >= 3000/uL

White blood cells (WBC) of 3000 per mcL

White blood cell (WBC) > 3500/ul

White blood cell (WBC) of 3000 per mcL

White blood cell (WBC) > 3,000/mcL or

White blood cell (WBC) > 3,000/mm^3

White blood cell (WBC) >= 2,000 cells/uL

White blood cells (WBCs) >= 2000 cells/uL

No exclusion for blood counts; however, at the time of treatment initiation, white blood cell (WBC) should be < 30,000/uL (can be controlled with hydroxyurea)

White blood cell count (WBC) >= 3500/ul

White blood cell (WBC) > 2,000/ul

White blood cell (WBC) >= 3,000

White blood count (WBC) > 2.5 x 10^9/L

White blood cell (WBC) greater than or equal to 3,000/ul

White blood cell (WBC) >= 3000/UL

WBC ?3,000/µl

Total white blood cell count (WBC) > 2000/mcL

White blood cells (WBC) >= 3.0 x 10^9/L

Subject has a white blood cell count > 25 × 10^9/L. Note: Hydroxyurea is permitted to meet this criterion.

White Blood Cell Count value of <15,000 cells/?L prior to Cycle 1 Day 1.

Absolute White blood cell (WBC) count ? 15 × 109/L (NOTE: Hydroxyurea is not allowed to attain a WBC count ? 15 x 109/L).

White blood cell (WBC) >= 2000/uL

WBC ? 2,500/mm^3

White blood cell (WBC) > 2,500 cells/mm^3

White blood cells (WBC) > 3,000/mcL

White blood cell count > 25 x 10e9/L or > 10% peripheral blood blasts;

White blood cell count (WBC) >= 3,000 cells/mcL

B-ALL patients must have an initial white blood cell count < 50,000/uL

White blood cell (WBC) count >= 2500/ul, obtained within 14 days prior to initiation of study treatment

White blood cells (WBCs) >= 2000 cells u/L

White blood cells (WBCs) >= 2000/uL

White blood cell (WBC) >= 2000/uL

White blood count (WBC) >= 3000/mm^3

White blood cells (WBC) >= 3,500/mcL

WBC ? 2500/?L

White blood cell (WBC) >= 3,000/mm^3

White blood cell (WBC) count >= 3.0 x 10^9/L

The use of hydroxyurea prior to study registration is allowed; patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment

White blood cells (WBCs) >= 2000/uL

Patients with a white blood cell count of more than 30 x 10^3 K/uL will not be eligible for this study

White blood cell (WBC) count >= 3.0 x 10^9/L

There are no minimum hematological parameter requirements prior to the first two cycles, as patients with AML and myelodysplastic syndrome (MDS) are understood to have low ANC and platelet counts when the disease is active; however, patients with white blood cell (WBC) greater than 50,000 will receive hydroxyurea to reduce the WBC count to below 50,000 at which point they may begin treatment

White blood cell (WBC) count >= 3.0 x 10^9/L

White blood count (WBC) >= 3,000/mm^3

White blood cell count (WBC) >= 4,000/ml

White blood cell (WBC) count >= 2000/uL

White blood cell (WBC) count ? 3 × 10e3/µL

White blood cells (WBC) > 3.0 ml

White blood cell (WBC) >= 3000/ul

Prior to cyclophosphamide and T cell infusions: white blood cells (WBC) =< 2000/uL

White blood cell count >= 2000/uL, obtained =< 21 days prior to registration and confirmed prior to the first dose of study drug

White blood count >= 3000

Within 14 days prior to registration: white blood cells (WBC) >= 2,000/uL

White blood cells (WBC) > 2000/uL

White blood cells (WBC) >= 4200/mm^3

Within 14 days prior to the first study treatment (cycle 1, day 1): White blood cells (WBC) counts > 2500/uL

White blood cells (WBCs) >= 2000/uL

White blood cells (WBC) > 3500/ul

White blood cells (WBC) < 2,000/ul

White blood cells (WBC) >= 2500 cells/ul

White blood cell count (WBC) >= 3,000/mm^3

White blood cell (WBC) >= 3,000/mcL

White blood cell (WBC) count of >= 3000/ul

White blood cell (WBC) > 2,000/ul

White blood cell (WBC) >= 3,000 cells/uL

Total white blood cell (WBC) count >= 3000/mm^3

White blood cells (WBC) >= 2500/uL

White blood cells (WBC) >= 2000/uL

White blood cells (WBC) >= 2000/ul

White blood cell (WBC) >= 3,000/ul

White blood cells (WBC) =< 1000/uL

COHORT A: White blood cells (WBC) >= 2000/uL

COHORT B: WBC >= 2000/uL

White blood cells (WBC) >= 3.0 x 10^9 cells/L

White blood cells (WBC) >= 3000/mm^3 within 4 weeks of enrollment

Obtained within 14 days prior to the first study treatment (cycle 1, day 1); white blood cell (WBC) counts > 2500/uL

White blood cell (WBC) count of >= 3000/ul

White blood cells (WBC) >= 2000/uL

White blood cell (WBC) >= 3,000/mcL

White blood cell (WBC) must be > 3500 cells/mm^3

White blood cell (WBC) >= 3,000/ul

White blood cell (WBC) >= 3000/mm^3

Whole blood cell (WBC) >= 3,000/ul

White blood cell count > 2,500/mcL

White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L

White blood cell (WBC) >= 3500 cells/mm^3 or >= 3.5 bil/L

White blood cell count of more than or equal to 3000/mm^3

White blood cells (WBC) < 2.0

STEP 2 ENROLLMENT AND RANDOMIZATION: white blood cells (WBC) >= 3,000/mm^3 within 3 weeks of study entry

White blood cell (WBC) >= 2000/mm^3

Peripheral white blood cell count =< 50,000/mcl

White blood cell count >= 1000/ul

White blood cell (WBC) count >= 3.0 x 10^9/L

White blood cells (WBC)\t>= 3000/uL

Obtained within 14 days prior to registration: White blood cells (WBC) >= 3,000/ul

White blood cell (WBC) = 2500 mm^3

White blood cell (WBC) >= 2000/uL

WBC at least 3,000/mm3

White blood cells (WBC) >= 2000/uL

White blood cell (WBC) <2,000/mm3

White blood cell (WBC) >= 3000/mm^3

White blood cells (WBC): >= 2000/uL (~ 2 x 10^9/L)

White blood cells (WBC) >= 3,000/ul

White blood cells (WBC) > 2.0 K/uL

Patients receiving hydroxyurea may continue receiving it for up to 14 days after the start of protocol treatment if white blood cells (WBC) > 30 x10^9/L

White blood cells (WBC) >= 3000/mm^3

EXPANSION COHORT ONLY: White blood cell (WBC) >= 3,00/mm^3

WBC >= 3,000/ul

White blood cells (WBC) < 2,500/mm^3

White blood cell (WBC) >= 2000/uL

Peripheral white blood cell (WBC) count 30,000/µL For cyto-reduction, hydroxyurea is allowed during screening and up to Cycle 1, Days 1-14, to reduce WBC count to < 30,000 µL prior to Day 1. After Cycle 1, Day 14, hydroxyurea is prohibited.

WBC > 11.0 × 10^9/L at screening.

White blood cell (WBC) counts > 2500/uL (obtained within 14 days prior to the first study treatment [course 1, day 1])

Within 14 days prior to enrollment/randomization: White blood cells (WBC) >= 3.0 K/uL

White blood cells (WBC) >= 2.0 x 10^3/uL

White blood cells (WBC) >= 2.0 x 10^3/uL

White blood count (WBC) >= 3,000/mm^3

White blood count (WBC) >= 3000/mm^3 (part 1 & 2)

White blood cell (WBC) > 1000/mm^3

DONOR: White blood cell count of >= 3,000

White blood count >= 3,000/mm^3

White blood cell (WBC) > 3000/ul

White blood cell (WBC) > 2000/mm^3

White blood cell count (WBC) >= 3000/mm^3

White blood cell (WBC) > 2000/uL

Lymphocytes < 15% of total white blood cells (WBCs) at baseline

WBC count <25,000 cells/mm3 (25 x 109/L)

White blood cells (WBC) >= 2000/mm^3

White blood cell (WBC): >= 2000/uL (~2 x 10^9/L)

White blood cell count >= 4000 x 10^6 cells/L

White blood cell (WBC) >= 2,000/mm^3

White blood cells (WBC) >= 3000/mm^3

White blood cell count > 3000/mm^3

White blood cell count (WBC) >= 3000/mm^3

DONOR: white blood cells (WBC) 4.0-10.0 x 10^3/mm^3

While blood cell (WBC) ? 3.0

While blood cell (WBC) < 2.0 x 10^9/L

White blood cells (WBC) >= 3000/mm^3

WBC ? 1.5 X10³/µL

White blood cell (WBC) ? 3,000/microL

White blood cell (WBC) < 2000/mcl

White Blood Count > 3,000/mm3

White blood cell (WBC) ? 4000/µL (? 4.0 x 103/µL)

They should have normal blood counts with a white blood cell (WBC) count of more than or equal to 3000/mm^3

White Blood Cells (WBC) ? 3.0x10E9/L including

White blood cells (WBC) (> 3000/mm^3)

White blood cell (WBC) count >= 3000 cells/mm^3

White blood cell (WBC) >= 2 K/microliter should be obtained with 28 days prior to randomization

White blood cell count (WBC) >= 3.0 x 10^9/L

White blood cell (WBC) count >= 3,500/mm^3

White blood cell (WBC) count >= 3000 cells/mm^3

White blood cell (WBC) >= 3.0 x 10^9/L

Total white blood cell count (WBC) >= 2.5 x 10^3/mm^3

White blood count (WBC) of > 2000 ul 3

White blood cell (WBC) >= 3000/uL

White blood cell count (WBC) should be lower than 30,000/mm^3 prior to initiation of cabozantinib (patients who are otherwise medically eligible for enrollment but have a WBC above 30,000/mm^3 are allowed concurrent treatment with hydroxyurea and/or 6-mercaptopurine to stabilize the WBC during the first 15 days of therapy; in these situations, hydroxyurea and/or 6-mercaptopurine will be discontinued once WBC is below 10,000/mm^3, and can be re-started if WBC again rises above 30,000/mm^3 during the first 15 days of therapy of the first cycle)

White blood cell (WBC) >= 2,000 /uL

White blood cells ? 2000/µL

White blood cells (WBC) >= 2.0

White blood cell count (WBC) >= 2.0

White blood cells (WBC) < 50,000/ul at screening

White blood cells greater than 1.5 x 10^3/ul (or 1,500 cells/mm^3); these results can be within last 60 days from the day of signing informed consent

White blood cell count (WBC) >= 2,000

White blood cell (WBC) >= 3000/mm^3

WBC count ? 3.0 x 103 cells/µL

White blood cell count >= 3.0 x 10^9/L

White blood count (WBC) >= 2.0 g/dL

Adequate baseline hematological parameters as defined by white blood cell count (WBC) ? 3.5 x 103/µL, lymphocyte count ? 1.0 x 103/µL, platelet count ? 100 x 103/µL, and hemoglobin ? 9 g/dL

White blood cell (WBC) >= 3,000/mm^3

Total white blood cell count (WBC) ? 3000/µl, or absolute neutrophil count (ANC) ? 1000/µl

Patients with symptoms/signs of hyperleukocytosis or white blood cell (WBC) > 100,000/uL can be treated with leukapheresis prior to enrollment

White blood cells (WBC) < 3.5/ml

WBC >/= 3,000/uL

A white blood cell (WBC) count <3 × 109/L, and / or platelet count <100 × 109/L if not due to hypersplenism.

White blood cell count (WBC) at initiation of treatment =< 10,000/L\r\n* If WBC is > 10,000/L patients may be started on leukapheresis or an appropriate dose of hydroxyurea (to be determined by the investigators), until WBC < 10,000/L, at which time the hydroxyurea will be discontinued for 12 hours prior to enrollment

Patients with symptoms/signs of hyperleukocytosis or white blood cells (WBC) > 100,000/uL can be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500 mg/m^2/dose) prior to enrollment

White blood cells (WBC) >= 3,000/mL

White blood cells (WBC) >= 2,000 cells/mm^3

White blood cell (WBC) >= 3.0 K/uL

White blood cell count (WBC) >= 3,000/mcL

Abnormal complete blood count; any of the following\r\n* Platelet count less than 75,000/ml\r\n* Hemoglobin (Hb) level less than 10 gm/dl\r\n* White blood cell (WBC) less than 3.5/ml

White blood cells (WBC) >= 3000/mm^3

White blood cell count > 3.0 k/mm3

White blood cell (WBC) > 3.0 K/uL

WBC > 3.0 K/uL

White blood cell count (WBC) >= 2,000/uL

White blood cells (WBC) >= 3,000/ul

White blood cell count (WBC) > 3,000/mm^3

White blood cell count (WBC) < 3500/ml

Total absolute phagocyte count (APC = %neutrophils + %monocytes) X white blood cell (WBC) is at least 1000/uL

White blood cell (WBC) >= 2000/uL

White blood cells (WBC) >= 3000/mm^3

White blood cell (WBC) >= 3000/mm^3

White blood cell (WBC) >= 3000/mm^3

White blood cells (WBC) < 4,000

White blood cells (WBC) >= 2000/uL

White blood cell (WBC) >= 2,000

White blood cell (WBC) >= 3 x 10^9/L

White blood cell (WBC) >= 3,000/uL

White blood cells (WBC) >= 3,000/uL

White blood cell (WBC) >= 1,500/mcL

White blood cells >= 2,000/mcL

White blood cell (WBC) > 3.0

Severe leukocytosis (white blood cell count [WBC] >= 20,000 cells /uL)

White blood cell (WBC) >= 3,500

White blood cells (WBCs) >= 2000/uL, obtained within 14 days of the first dose of study drug

White blood cell count (WBC) > 4000/mm^3

White blood cells (WBC) >= 3 x 10^9/L, transfusions and growth factors are allowed

White blood cells (WBCs) < 3.0 K/UL in the past 30 days

White blood cell count (WBC) >= 3.0 K/mm^3

White blood cell (WBC) > 2.0 k/uL

White blood cells (WBCs) < 3.0 K/UL in the past 30 days

White blood cell (WBC) ? 3,500 x10^9/L

White blood cell (WBC) >= 3,500/mm^3

Total white blood cells (WBC) >= 4.0 x 10^3/mcL within 28 days prior to registration

Extreme hyperleukocytosis, white blood cell (WBC) counts over 200 x 109/L (200,000/microL) at the time of enrollment

Leukocytes (white blood cells [WBC]) >= 3,000/uL (>= 2,500/uL for African-American participants)

White blood cells >= 3,000/microliter

White blood cell (WBC) >= 2,500/uL

Leukocytes (white blood cell [WBC]) >= 3,000/microliter

White blood cell (WBC) >= 3000/mm^3 within 90 days of enrollment

White blood cells (WBC) within institutional limits of normal or judged to be not clinically significant by the investigator

White blood cell (WBC) < 2.5

Peripheral blood white blood cells (WBC) greater than 2,000 per microliter (required for collection of dendritic cell precursors)

White blood cells (WBC) >= 3000/mm^3

Leukocytes >= 3,000/uL; Note: if leukopenia is idiopathic and no other significant co-morbidities exist patients will not be excluded on the basis of their white blood cell (WBC)

White blood cell count (WBC) >= 3,000/ul

White blood cells (WBC) > 1500 cells/uL

White blood cell (WBC) > 2.5 B/L (10^9/L)

Absolute WBC (white blood cell) count ? 20 x 109/L

Within 30 days of eligibility confirmation: Leukocytes (white blood cells [WBC]) >= 3,000/uL

Obtained within 28 days prior to registration: White blood cell (WBC) >= 2500 cells/uL

White blood cells >= 3,000/uL

White blood cell (WBC) >= 3.0 x 109/L

White blood cell (WBC) >= 3000/mm^3

White blood cell count > 3000/mm^3

White blood cell (WBC) within normal limits

White blood cell count > 3000/mm^3

White blood cell count >= 3.0 K/cu mm

White blood cell (WBC): 3000 – 10,000

White blood cell count >= 3.0 K/cu mm

White blood cell (WBC) count ? 20 x 10E3/µL

White blood cell >= 2,000 /mm^3 without transfusion support > 7 days prior to registration

White blood cells (WBC) > 2.0 X 10^3/uL

WBC < 3000/?L

White blood cell (WBC) >= 4000 mm^3 or granulocyte count at least 2,000/mm^3

White blood cell (WBC) < 3000/uL

White blood count >= 1,500/mm^3

White blood count > 1,500/mm^3

Participants with AML must either refuse or not be considered candidates for intensive induction chemotherapy. Previously treated participants should have evidence of persistent or recurrent AML in the peripheral blood and/or bone marrow. Participants must have white blood cell (WBC) < 15 x 10^9cells/L.

White blood cell (WBC) >= 3,000/uL, performed within 28 days prior to registration

Leukopenia (white cell count < 4,000 cells/uL)

progressive leukocytosis, defined as increasing white blood cell (WBC) count on at least 2 consecutive evaluations, at least 2 weeks apart and doubling from the nadir to ?20000/?L or absolute increase in WBC by ?50000/?L above the post-treatment nadir

Total White Blood Cell count (WBC) < 25 x 109/L prior to first infusion. Prior or concurrent treatment with hydroxyurea to achieve this level is allowed.

White Blood Cell Count value of <15,000 cells/?L prior to Cycle 1 Day 1.